KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Receivables (2016 - 2026)

Amgen has reported Receivables over the past 18 years, most recently at $9.1 billion for Q1 2026.

  • For Q1 2026, Receivables rose 12.37% year-over-year to $9.1 billion; the TTM value through Mar 2026 reached $9.1 billion, up 12.37%, while the annual FY2025 figure was $9.6 billion, 37.11% up from the prior year.
  • Receivables for Q1 2026 was $9.1 billion at Amgen, down from $9.6 billion in the prior quarter.
  • Over five years, Receivables peaked at $9.6 billion in Q4 2025 and troughed at $5.1 billion in Q1 2022.
  • A 5-year average of $7.0 billion and a median of $6.9 billion in 2024 define the central range for Receivables.
  • Biggest five-year swings in Receivables: dropped 10.17% in 2024 and later soared 37.11% in 2025.
  • Year by year, Receivables stood at $5.7 billion in 2022, then soared by 36.51% to $7.8 billion in 2023, then fell by 10.17% to $7.0 billion in 2024, then soared by 37.11% to $9.6 billion in 2025, then dropped by 4.51% to $9.1 billion in 2026.
  • Business Quant data shows Receivables for AMGN at $9.1 billion in Q1 2026, $9.6 billion in Q4 2025, and $8.5 billion in Q3 2025.